ClinicalTrials.gg
RecruitingNCT07276282ZEPHYRUpdated Mar 23, 2026

Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction

A Phase 3 interventional study of Ziltivekimab and Placebo in Coronary Artery Disease, Acute Myocardial Infarction (AMI) and Coronary Atherosclerosis of Native Coronary Artery, sponsored by ECRI bv. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-23.

Sponsored by ECRI bv · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
332
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 177 studies in Coronary Artery Disease with a site in Switzerland — 31 open to participants now, 41 under way, 4 of them phase 3. Coronary Artery Disease · Switzerland.

Planned enrollment
60th of 125
332 · median 296
Started
2025
with 5 others
Phase 3
15 of 177
2 open now
Primary completion
2028-09
later than 27 of 40 live
Registered
169th of 177
by date
Lead sponsor
5 of 177
ECRI bv

Among the 177 studies in Coronary Artery Disease with a site in Switzerland, this one is the 60th largest by planned enrollment of the 125 interventional ones that give a count, is one of 6 that started in 2025, is one of 15 in phase 3, reaches primary completion later than 27 of the 40 other live ones, and was the 169th registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

31 of the 177 studies in Coronary Artery Disease with a site in Switzerland are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 177 studies in Coronary Artery Disease with a site in Switzerland, or all of them as a file.
02

Study summary

Despite improvements in the treatment, coronary artery disease (CAD) remains one of the leading causes of death worldwide. Around 20% of people who have suffered a heart attack (myocardial infarction) need to be hospitalized again within a year, and 10% experience another heart attack. Despite currently available medication, patients remain at risk of further episodes after a heart attack. Scientists have discovered that inflammation in the body plays a decisive role in the development and narrowing of arterial blockages (atherosclerosis). This study aims to investigate whether a new treatment that reduces inflammation can help improve the arteries of patients with CAD.

This study will examine whether blocking certain inflammation-related substances with a new medicinal product called ziltivekimab affects the buildup and composition of plaques (fatty deposits) in the coronary arteries. Special imaging diagnostic techniques will be used to look inside the arteries and check whether the treatment helps reduce the narrowing caused by dangerous plaques, which can lead to future heart attacks.

This is a clinical study in which participants are randomly divided into two groups (randomization): one group will receive the new treatment ziltivekimab and other group will receive a placebo (a harmless substance with no active ingredients). Both groups will continue to receive standard treatment for heart attacks. The study lasts approximately 15 months per participant.

The full scientific title of the trial is: Effects of ziltivekimab versus placebo on coronary atherosclerosis in patients with acute myocardial infarction. A study with serial multi-vessel imaging obtained using intravascular ultrasound, near-infrared spectroscopy, and optical coherence tomography techniques.

Read the detailed description

Despite advances in cardiovascular care and preventive treatments, coronary artery disease (CAD) still represents the leading causes of death worldwide. Almost one fifth of patients with acute myocardial infarction (MI) suffer from rehospitalization within 1 year and 10% from recurrent MI. This residual cardiovascular risk persists regardless of optimal medical therapy with contemporary pharmacologic treatments including lipid lowering drugs, suggesting that this excess risk is mediated through pathways not yet directly addressed by current management. Inflammation is now a well-acknowledged major contributor to atherosclerosis development and plaque progression/instability, with both the innate (monocyte-derived macrophages) and the acquired immune system (T-cells) thought to be involved. Within atherosclerotic human plaques, activated monocyte-derived macrophages, specialized CD4+ and CD8+ T-cells produce a wide array of chemokines and cytokines with pro-inflammatory effects.

Despite a growing body of evidence that has confirmed anti-inflammatory therapy as a new cornerstone opportunity to reduce effectively the residual cardiovascular risk in CAD patients with CAD treated with optimal medical therapy, the direct effect of these therapies on atherosclerosis extension and composition is largely unknown. Convincing experimental evidence has raised the translational hypothesis of a direct favourable effect of IL-6 inhibition on plaque biology and stabilization. However, in-human data regarding the mechanistic role of anti-IL-6 agents on coronary atherosclerosis are lacking so far.

The purpose of this study is to investigate for the first time the in-vivo effects of IL-1/IL-6 pathway inhibition on coronary plaque morphology and composition in patients with CAD. Serial multi-vessel images obtained with multimodality intracoronary imaging will allow for a comprehensive evaluation of presumed high risk atherosclerotic features such as plaque burden, fibrous cap thickness, lipid content and local inflammation. An intracoronary serial imaging study may elucidate the exact pathophysiological underpinnings of atheroprotection beyond lipid lowering therapy and assess whether an effective anti-inflammatory therapy can improve the atherosclerotic profile of patients with CAD.

This is an interventional, randomised, parallel-group, double-blind, placebo-controlled, multi-centre, multi-national study designed to evaluate the effects of ziltivekimab versus placebo (randomised 1:1), both administered s.c. once-monthly and added to standard of care, on change in percent atheroma volume (PAV) as well as change in maxLCBI and fibrous cap thickness. The initial dose of ziltivekimab s.c./placebo to be administered at randomisation which is as early as possible and latest within 48 hours after the index PCI procedure, followed by once-monthly administration during the treatment period.

03

Conditions studied

  • Coronary Artery Disease
  • Acute Myocardial Infarction (AMI)
  • Coronary Atherosclerosis of Native Coronary Artery

Keywords

  • IL-6 inhibition
  • atherosclerosis
  • acute myocardial infarction
  • anti-inflammatory
  • intracoronary imaging
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • obtained before any study-related activities.
  • Age 18 years or above at the time of providing informed consent.
  • Acute myocardial infarction, with at least one coronary segment (culprit lesion) treated with PCI.
  • At least two major native coronary arteries each meeting angiographic criteria for intracoronary imaging immediately following the qualifying PCI procedure.

Key Exclusion Criteria:

  • Known or suspected to study intervention(s) or related products.
  • Known allergy to contrast medium, heparin, aspirin, ticagrelor or prasugrel.
  • Female of .
  • Left-main disease.
  • Three-vessel disease.
  • History of coronary artery bypass surgery.
  • TIMI flow \<2 of the infarct-related artery after PCI.
  • Unstable clinical status (hemodynamic or electrical instability.
  • Significant coronary calcification or tortuosity deemed to preclude IVUS, NIRS and OCT evaluation.
  • Uncontrolled cardiac arrhythmia.
  • Severe kidney impairment.
  • Active liver disease or hepatic dysfunction.
  • Current use of anti-IL-6 products or anticipated use of such drugs any time during the study.
  • Use of systemic drugs or disease modifying anti-rheumatic drugs or anticipated chronic use of such drugs any time during the study.
  • Known, or suspicion of, active infection or major hematologic, metabolic, or endocrine dysfunction in the judgment of the Investigator
  • History of recurrent serious infections.
  • Use of preventive systemic antibiotics, systemic antivirals, or systemic antifungals.
  • Known (acute or chronic) or
  • Planned surgery within 12 months from the time of screening.
  • History of cancer within the past 5 years, except for adequately treated basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, low risk prostate cancer, or carcinoma in situ/high grade prostatic intraepithelial neoplasia (PIN) at the discretion of the investigator.
  • Estimated less than 2 years
  • Received a live or attenuated- product within 4 weeks of study intervention administration or expected to receive a live or attenuated-live vaccine product during the treatment period.
  • Major cardiac surgical within the past 60 days or any major surgical procedure planned at the time of randomisation or as treatment for the current AMI (CABG).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
332 participants (estimated)

Study arms

  • Experimental
    Ziltivekimab Arm

    Participants will receive Ziltivekimab subcutaneously once per month

    Drug: Ziltivekimab

  • Placebo comparator
    Placebo Arm

    Participants will receive placebo subcutaneously once per month

    Drug: Placebo

Interventions

  • Ziltivekimab is administered subcutaneously (i.e., under the skin) once per month added to standard of care.

  • DrugPlacebo

    Placebo is administered subcutaneously (i.e., under the skin) once per month added to standard of care.

06

What researchers measure

Primary outcomes

  1. Change in percent atheroma volume

    Change in percent atheroma volume (PAV) as determined by greyscale intravascular ultrasound (IVUS) in matched regions of interest. Theoretical change is between -100% to +100%. Typical range around -2% to +2%. A lower (more negative) change in PAV is better.

    Time frame: From randomization (week 0) to end-of-study (52-week)

Secondary outcomes

  1. Maximum lipid core burden index

    Change in maximum lipid core burden index (LCBI) in any 4-mm segment (maxLCBI4mm) as determined by NIRS in matched regions of interest. Theoretical range is between -1000 to +1000. Typical range around -250 to +250. A lower (more negative) change is better.

    Time frame: From randomisation (week 0) to end-of-study (52-week)

  2. Minimal fibrous cap thickness

    Change in minimal fibrous cap thickness as determined by optical coherence tomography (OCT) in matched regions of interest. Theoretical range is between -500 µm to +500 µm. Typical range around -50 µm to +110 µm. A higher (positive) change is better; it indicates fibrous cap thickening (increased plaque stability).

    Time frame: From randomisation (week 0) to end-of-study (52-week)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Sep 2028, 32 months after the start.

Of 29 industry-sponsored phase 3 interventional studies under Coronary Artery Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 32 months is below that.

Counting every sponsor, half of 61 studies reached it within 47 months; a quarter within 20 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2025
First posted
Dec 11, 2025
StartActual
Dec 19, 2025
Primary completionEst.
Sep 1, 2028
CompletionEst.
Dec 1, 2028
Last update
Mar 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07276282
Lead sponsor
ECRI bv
Responsible party
Sponsor
First posted
Dec 11, 2025
Start date
Dec 19, 2025
Primary completion
Sep 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Mar 23, 2026

Study contacts

Anita Dekker
Contact
adekker@cardialysis.nl
31102062828
Ernest Spitzer, MD
Contact
e.spitzer@ecri-trials.com
31102062828
Lorenz Räber, MD, PhD
principal investigator · Cardiology Department, Bern University Hospital, Inselspital Bern, Switzerland
Ernest Spitzer, MD
study director · European Cardiovascular Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziltivekimab

Start the discussion